We are live on
!
Find out more
VC
Vivo Capital Portfolio holdings
AUM
$1.2B
1-Year Est. Return
911.44%
This Fund
S&P 500
This Quarter
Est. Return
+26.18%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$706M
AUM Growth
+$239M
(+51%)
Cap. Flow
+$173M
Cap. Flow
% of AUM
24.55%
Top 10 Holdings %
Top 10 Hldgs %
75.21%
Holding
36
New
6
Increased
3
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
|
+$135M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$22.5M |
| 3 |
Q32 Bio
QTTB
|
+$21.7M |
| 4 |
Arrowhead Research
ARWR
|
+$11.7M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$9.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AAAP
Advanced Accelerator Applications S.A.
AAAP
|
+$20.3M |
| 2 |
AIMT
Aimmune Therapeutics
AIMT
|
+$11.9M |
| 3 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$4M |
| 4 |
CRISPR Therapeutics
CRSP
|
+$2.31M |
| 5 |
KALA BIO
KALA
|
+$1.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.38% |
| 2 | Materials | 2.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
| $4.21M | 0.6% |
105,000
| – | – |
|
|
AGRX
27
DELISTED
Agile Therapeutics
AGRX
| $3.89M | 0.55% |
757
| – | – |
|
|
TMBR
28
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
| $3.73M | 0.53% |
1,075
+155
| +17% | +$460K |
|
29
Madrigal Pharmaceuticals
MDGL
$10.8B
| $3.18M | 0.45% |
+27,220
| New | +$3.36M |
|
|
KALV
30
DELISTED
KalVista Pharmaceuticals
KALV
| $2.85M | 0.4% |
300,325
| – | – |
|
|
TRVN
31
DELISTED
Trevena, Inc.
TRVN
| $2.83M | 0.4% |
2,765
| – | – |
|
|
AKTX
32
Akari Therapeutics
AKTX
$13.8M
| $629K | 0.09% |
432
| – | – |
|
|
VIRX
33
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $532K | 0.08% |
5,585
-8,701
| -61% | -$1.49M |
|
|
SLNOW
34
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
| $23K | ﹤0.01% |
188,772
| – | – |
|
|
35
CRISPR Therapeutics
CRSP
$4.73B
| – | – |
-98,511
| Closed | -$2.31M |
|
|
AAAP
36
DELISTED
Advanced Accelerator Applications S.A.
AAAP
| – | – |
-249,241
| Closed | -$20.3M |
|
Similar funds
SGDR
FCCPG
AIM
CA
SC
HCM
MB
CCM
Vivo Capital's Q1 2018 Portfolio in Review
As of Q1 2018, Vivo Capital held 36 positions worth $706M, up 51% from $467M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Vivo Capital deployed $173M of net new capital in Q1 2018, opening 6 new positions and adding to 3 existing holdings. Its largest new stake was Yarrow Bioscience, Inc. Common Stock: 1,114 shares worth $151M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier, followed by Materials.
On the sell side, the largest reduction was Aimmune Therapeutics, an estimated $11.9M trimmed.
- Vivo Capital's largest Q1 2018 buy was Yarrow Bioscience, Inc. Common Stock: 1,114 shares worth $151M.
- Vivo Capital added most to Ascendis Pharma A/S in Q1 2018, an estimated $22.5M increase.
- Vivo Capital's biggest Q1 2018 reduction was Aimmune Therapeutics, cutting an estimated $11.9M.
- Vivo Capital fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $20.3M.
- Vivo Capital's ten largest holdings make up 75% of its $706M portfolio in Q1 2018.
- Vivo Capital opened 6 new positions and closed 2 in Q1 2018.
- Vivo Capital's portfolio value rose 51% quarter-over-quarter to $706M.
Based on Vivo Capital's 13F filing for Q1 2018, filed 15 May 2018.